Switch theme
Sign up to access all valuation multiples
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women’s health.
2005
23
LTM Revenue $0.5M
Last FY EBITDA -$23.4M
$19.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dare Bioscience has a last 12-month revenue (LTM) of $0.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Dare Bioscience achieved revenue of $10K and an EBITDA of -$23.4M.
Dare Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dare Bioscience valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.5M | XXX | $10K | XXX | XXX | XXX |
| Gross Profit | $0.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$23.4M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -239260% | XXX | XXX | XXX |
| EBIT | -$23.4M | XXX | -$23.5M | XXX | XXX | XXX |
| EBIT Margin | -4977% | XXX | -239692% | XXX | XXX | XXX |
| Net Profit | -$11.9M | XXX | -$4.1M | XXX | XXX | XXX |
| Net Margin | -2535% | XXX | -41431% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Dare Bioscience's stock price is $3.
Dare Bioscience has current market cap of $26.3M, and EV of $19.5M.
See Dare Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $19.5M | $26.3M | XXX | XXX | XXX | XXX | $-1.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Dare Bioscience has market cap of $26.3M and EV of $19.5M.
Dare Bioscience's trades at 1995.9x EV/Revenue multiple, and -0.8x EV/EBITDA.
Equity research analysts estimate Dare Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dare Bioscience has a P/E ratio of -2.2x.
See valuation multiples for Dare Bioscience and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $26.3M | XXX | $26.3M | XXX | XXX | XXX |
| EV (current) | $19.5M | XXX | $19.5M | XXX | XXX | XXX |
| EV/Revenue | 41.6x | XXX | 1995.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.8x | XXX | XXX | XXX |
| EV/EBIT | -0.8x | XXX | -0.8x | XXX | XXX | XXX |
| EV/Gross Profit | 41.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.2x | XXX | -6.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 4.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDare Bioscience's last 12 month revenue growth is 2335%
Dare Bioscience's revenue per employee in the last FY averaged $0K, while opex per employee averaged $1.0M for the same period.
Dare Bioscience's rule of 40 is 1235% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dare Bioscience's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Dare Bioscience and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2335% | XXX | 5060% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -239260% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 1235% | XXX | -236924% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 145188% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 239792% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dare Bioscience acquired XXX companies to date.
Last acquisition by Dare Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Dare Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Dare Bioscience founded? | Dare Bioscience was founded in 2005. |
| Where is Dare Bioscience headquartered? | Dare Bioscience is headquartered in United States of America. |
| How many employees does Dare Bioscience have? | As of today, Dare Bioscience has 23 employees. |
| Who is the CEO of Dare Bioscience? | Dare Bioscience's CEO is Ms. Sabrina Martucci Johnson. |
| Is Dare Bioscience publicy listed? | Yes, Dare Bioscience is a public company listed on NAS. |
| What is the stock symbol of Dare Bioscience? | Dare Bioscience trades under DARE ticker. |
| When did Dare Bioscience go public? | Dare Bioscience went public in 2014. |
| Who are competitors of Dare Bioscience? | Similar companies to Dare Bioscience include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Dare Bioscience? | Dare Bioscience's current market cap is $26.3M |
| What is the current revenue of Dare Bioscience? | Dare Bioscience's last 12 months revenue is $0.5M. |
| What is the current revenue growth of Dare Bioscience? | Dare Bioscience revenue growth (NTM/LTM) is 2335%. |
| What is the current EV/Revenue multiple of Dare Bioscience? | Current revenue multiple of Dare Bioscience is 41.6x. |
| Is Dare Bioscience profitable? | Yes, Dare Bioscience is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
